Adriamycin+Cyclophosphamide>Docetaxel — Competitive Intelligence Brief

Adriamycin+Cyclophosphamide>Docetaxel (Adriamycin+Cyclophosphamide>Docetaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination regimen. Area: Oncology.

phase 3 Chemotherapy combination regimen Oncology Small molecule

Target snapshot

Adriamycin+Cyclophosphamide>Docetaxel (Adriamycin+Cyclophosphamide>Docetaxel) — Asan Medical Center. This sequential chemotherapy regimen uses anthracycline and alkylating agents followed by a taxane to damage cancer cell DNA and disrupt microtubule formation, inducing apoptosis in rapidly dividing cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adriamycin+Cyclophosphamide>Docetaxel TARGET	Adriamycin+Cyclophosphamide>Docetaxel	Asan Medical Center	phase 3	Chemotherapy combination regimen
TC chemotherapy	TC chemotherapy	Agendia	marketed	Chemotherapy combination regimen
TC	TC	AGO Study Group	marketed	Chemotherapy combination regimen
Dose dense AC	Dose dense AC	Ottawa Hospital Research Institute	marketed	Chemotherapy combination regimen
Idarubicine plus Cytarabine regimen	Idarubicine plus Cytarabine regimen	The First Affiliated Hospital of Soochow University	phase 3	Chemotherapy combination regimen (anthracycline + nucleoside analog)	Topoisomerase II (idarubicin); DNA polymerase (cytarabine)
AG chemotherapy	AG chemotherapy	Zhejiang Cancer Hospital	phase 3	Chemotherapy combination regimen
FOLFOX/XELOX/Capecitabine	FOLFOX/XELOX/Capecitabine	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	phase 3	Cytotoxic chemotherapy combination regimen	Thymidylate synthase (5-FU component); DNA (oxaliplatin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination regimen class)

1. Tianjin Medical University Cancer Institute and Hospital · 2 drugs in this class
2. Agendia · 1 drug in this class
3. Asan Medical Center · 1 drug in this class
4. Children's Cancer Group, China · 1 drug in this class
5. China Breast Cancer Clinical Study Group · 1 drug in this class
6. Fujian Medical University · 1 drug in this class
7. MIPO Clinic · 1 drug in this class
8. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
9. Ottawa Hospital Research Institute · 1 drug in this class
10. Pfizer · 1 drug in this class